MPL and autoimmune thrombocytopenic purpura: We suppose that TRAs may not be so effective for treating CIT caused by carboplatin as for AA or ITP since both c-Mpl and JAK/STAT pathway are prominently downregulated after exposure to carboplatin and fails to be re-activated even TPO is administered in our study.